Biotechnology Sector Outlook — September 2026

Read the report

SlidesScroll

1 of 21

←→Full screen

HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY

Biotechnology: An Expectations Story, Not a Markdown

What the market pays for across the biotechnology set on forward revenue, what separates the premium end from the discount end, and what the recent deal tape shows about buyer behaviour.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-15 · primary valuation basis EV / Revenue (CY2027E)

Biotechnology Coverage | September 2026 | Confidential

Sources & methodology

1

← Previous

1 / 21 · HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY

Next →

What each page shows

The analyst’s walkthrough of the deck, page by page.

1. 01

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY

   Cover page introducing the September 2026 biotechnology sector outlook.

   We're opening our September 2026 biotechnology outlook: an expectations story, not a markdown. Over the sections that follow we show what the market pays for on forward revenue, what separates the premium end from the discount end, and what the recent deal tape says about buyer behaviour.

   Everything on this page

   HEALTH CARE › PHARMACEUTICALS, BIOTECHNOLOGY AND LIFE SCIENCES › BIOTECHNOLOGY Biotechnology: An Expectations Story, Not a Markdown What the market pays for across the biotechnology set on forward revenue, what separates the premium end from the discount end, and what the recent deal tape shows about buyer behaviour. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-15 · primary valuation basis EV / Revenue (CY2027E) Biotechnology Coverage | September 2026 | Confidential Sources & methodology 1

2. 02
   CONTENTS

   What This Report Covers

   Contents page listing the report's five sections plus the appendix.

   This report runs five sections plus an appendix: the bottom line, the landscape, valuation and situations, the deal tape, and strategic implications. We lead with the bottom line so a reader who stops there still leaves with the whole story.

   Everything on this page

   CONTENTS What This Report Covers 01 The Bottom Line One Business Model Sets This Tape, and Proof Is What Earns the Premium 02 The Landscape Clinical-Stage Developers Dominate the Count; Three Small Neighbours Sit Beside Them 03 Valuation & Situations Pricing Splits Three Ways Across the Names Carrying CY2027E Revenue Estimates 04 The Deal Tape Buyers Paid for Resolved Science, from Small Bolt-Ons to Multi-Billion Purchases 05 Strategic Implications What This Evidence Changes for Owners, Management Teams and Buyers 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Biotechnology Coverage | September 2026 | Confidential Sources & methodology 2

3. 03
   01 · THE BOTTOM LINE

   Clinical-Stage Developers Set This Tape; Diversified Commercial Biopharma Anchors the Middle

   This page summarizes the report's core finding: clinical-stage developers set the tape while diversified commercial biopharma anchors the middle.

   We start with the headline: clinical-stage developers set this tape, and diversified commercial biopharma anchors the middle. On the nine names carrying CY2027E revenue estimates, the premium three trade at 23.3x EV/Revenue against 2.6x for the discount three, so the split runs on durability rather than one fast year. Faster growers at 7.4x versus 4.3x for slower ones shows growth is priced, but the step is modest, so the market is also paying for confidence in the next readout. So what: this cohort behaves like a probability market, not a conventional revenue-multiple story.

   Everything on this page

   01 · THE BOTTOM LINE Clinical-Stage Developers Set This Tape; Diversified Commercial Biopharma Anchors the Middle The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Qualitative characterisations are NeuraCap views. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 3 1 The Two Ends of This Set Do Not Trade Alike On the 9 names carrying CY2027E revenue estimates, the three at the premium end sit at 23.3x EV / Revenue and the three at the discount end at 2.6x. A forward multiple already credits the growth in the estimate, so a premium that survives it points to durability rather than one fast year. 2 Faster Growers Are Paid More, but the Step Is Modest Split those same 9 names at 14% forward revenue growth and the 5 faster growers sit at 7.4x EV / Revenue against 4.3x for the 4 slower ones. The gap is real and contained, which says pricing here tracks the credibility of the next readout as much as the growth line itself. 3 One Business Model Is 91% of the Names Clinical-stage therapeutics developers account for 77 of the 85 companies in scope, and the middle of that group sits at 4.5x EV / Revenue. Buyers here are underwriting probability-weighted pipeline value and cash runway to the next value-inflecting milestone, not an earnings stream. 4 What Buyers Paid for Whole Companies Sits Either Side of the Public Range 2 of the 9 records on this deal tape carry a disclosed revenue multiple, struck at 24.0x and 4.9x EV / Revenue. Large-cap and mid-cap biopharma replenishing pipeline ahead of loss of exclusivity is the structural buyer, and the tape shows it acting in two motions — partner first, acquire once a readout resolves. 4.5x Sector median EV/Revenue CY2027E consensus · 9 rated of 85 companies 23.3x Premium tier median vs 2.6x discount top quartile (n=3) against bottom quartile (n=3) — the spread the report explains 27 Recorded transactions in this tier told as case studies in the deal section; the full tape is in the appendix

4. 04
   SECTION 02

   02

   Section divider introducing the market landscape and business-model segmentation.

   We now turn to the landscape: who is in scope, and what question each business-model group is priced on. Clinical-stage developers dominate the count, with three smaller neighbouring segments sitting beside them.

   Everything on this page

   SECTION 02 02 THE LANDSCAPE Clinical-Stage Developers Dominate the Count; Three Small Neighbours Sit Beside Them Who is in scope, and what question each group is priced on. 02 of 06 Biotechnology Coverage | September 2026 | Confidential Sources & methodology 4

5. 05
   02 · MARKET MAP

   Four Business Models Share One Label, and Each Is Priced on a Different Question

   This page groups the covered companies into four business models and shows the median EV/Revenue for each.

   We group the covered universe into four business models, each priced on a different question. Clinical-stage therapeutics developers carry the bulk of the count, while diversified commercial biopharma, biosimilars and specialty biologics, and one adjacent diagnostics name make up the rest. Grouping by business model rather than by label is what lets us compare like against like on EV/Revenue. So what: an investor evaluating this sector needs to know which question they're actually pricing before they look at any single multiple.

   Everything on this page

   02 · MARKET MAP Four Business Models Share One Label, and Each Is Priced on a Different Question 85 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 5 CLINICAL-STAGE THERAPEUTICS DEVELOPERS 77 cos median 4.5x REGN MRNA ASND BLTE CELC SRPT IRON GERN INO EYPT ACOG MNOV +65 more 77 of the 85 names in scope: value steps at readouts and agency decisions, so runway and probability of success sit inside the multiple. BIOSIMILARS AND SPECIALTY BIOLOGICS 5 cos no rated names ALVO EBS EOLS HCM LNTH 5 names where manufacturing security, cost of goods and biologics data exclusivity timing shape the revenue tail. DIVERSIFIED COMMERCIAL-STAGE BIOPHARMA 2 cos median 5.1x AZN AMGN 2 names with marketed portfolios; they anchor the middle of the range and source pipeline from everyone else. ADJACENT: DIAGNOSTICS AND RESEARCH TOOLS 1 cos no rated names OPK A single adjacent name, useful as a boundary marker for the set rather than as a like-for-like comparable.

6. 06
   02 · LANDSCAPE

   The Sector Is One Dominant Business Model Plus Three Small Neighbours

   This page details the segment view of the approved universe, showing one dominant business model plus three small neighbours.

   The sector is overwhelmingly one business model: clinical-stage therapeutics developers account for 91% of the companies in scope. The remaining three segments — diversified commercial biopharma, biosimilars and specialty biologics, and one adjacent diagnostics and research tools name — sit alongside as small neighbours. This concentration means most of what moves this sector moves on pipeline and clinical readouts, not on quarterly earnings. So what: understanding the shape of this universe is the first step before any multiple can be trusted.

   Everything on this page

   02 · LANDSCAPE The Sector Is One Dominant Business Model Plus Three Small Neighbours Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Clinical-stage therapeutics developers 77 91% 4.5x Regeneron Pharmaceuticals, Inc. (REGN) · Moderna, Inc. (MRNA) · +75 more The tape's centre of gravity. 91% of the names in scope develop therapeutics ahead of, or alongside, first commercial revenue, and the middle of the 7 covered names here sits at 4.5x EV / Revenue on CY2027E. Because approval is gated by agency decisions, the multiple is carrying a view on probability, mechanism differentiation and cash runway to the next readout. Biosimilars and specialty biologics 5 6% — Alvotech (ALVO) · Emergent BioSolutions Inc. (EBS) · +3 more Five names, no covered multiple. Alvotech, Emergent BioSolutions Inc., Evolus, Inc., HUTCHMED (China) Limited and Lantheus Holdings, Inc. sit here, and none of the 5 carries a CY2027E revenue estimate in this set. Value in this group leans on inspection-ready manufacturing, supply security and the timing of biosimilar entry rather than on a single binary readout. Diversified commercial-stage biopharma 2 2% 5.1x AstraZeneca PLC (AZN) · Amgen Inc. (AMGN) Two names anchor the middle. AstraZeneca PLC (AZN) and Amgen Inc. (AMGN) are both covered and price at 5.1x EV / Revenue in the middle of this pair. They are the reference point for what a marketed, payer-negotiated portfolio is worth in this set, and they are also the counterparties most motivated to buy pipeline elsewhere. Adjacent: diagnostics and research tools 1 1% — OPKO Health, Inc. (OPK) One adjacent comparison point. OPKO Health, Inc. (OPK) is the single adjacent name in scope and carries no CY2027E revenue estimate here. Treat it as an edge of the map: the economics are service and testing volume rather than probability-weighted program value, so it frames the set rather than sets its pricing.

7. 07
   SECTION 03

   03

   Section divider introducing the valuation and situation analysis.

   Next we turn to pricing: how the market splits value across the names carrying CY2027E revenue estimates. Premium, core and discount tiers on EV/Revenue set up the situation map that follows.

   Everything on this page

   SECTION 03 03 VALUATION & SITUATIONS Pricing Splits Three Ways Across the Names Carrying CY2027E Revenue Estimates Premium, core and discount, on EV / Revenue for CY2027E. 03 of 06 Biotechnology Coverage | September 2026 | Confidential Sources & methodology 7

8. 08
   03 · PUBLIC MARKET VALUATION

   The Premium End Prices Proof; The Discount End Prices Risk, Not Slow Growth

   This page ranks the rated companies by EV/Revenue and shows the sector median.

   Across the rated companies, EV/Revenue on CY2027E consensus ranges from a premium tier down to a discount tier, with the sector median sitting at 4.5x. The premium end, at 23.3x, is pricing proof — durability that has survived being credited into the estimate. The discount end, at 2.6x, is pricing risk rather than slow growth, sitting well below the sector median on the same basis. So what: the spread here is a read on confidence in the pipeline, not a simple growth ranking.

   Everything on this page

   03 · PUBLIC MARKET VALUATION The Premium End Prices Proof; The Discount End Prices Risk, Not Slow Growth EV / Revenue (CY2027E) · all 9 rated companies, sorted descending · sector median 4.5x · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 8 PREMIUM · median 23.3x CORE · median 4.5x DISCOUNT · median 2.6x Sector median 4.5x WHAT SEPARATES THE TWO ENDS The premium end sells proof. Ascendis Pharma A/S (ASND) pairs 47% forward revenue growth with a 42% margin and sits at the premium end alongside Moderna, Inc. (MRNA) and MediciNova, Inc. (MNOV). Because a forward lens already credits the growth in the estimate, a premium that survives it reads as the market paying for a package it can underwrite — mechanism, pathway and a sequenced catalyst calendar. The discount end still grows fast. Speed alone does not lift the multiple here: Alpha Cognition Inc. (ACOG) at 92% forward growth and Geron Corporation (GERN) at 45% both price at the discount end of the 9 covered names. Single-asset concentration, financing overhang and an unsettled registrational picture are associated with that gap far more than the growth line is. Falling revenue prices at the bottom. Sarepta Therapeutics, Inc. (SRPT) carries revenue at -24% with a 24% margin and sits at the discount end of the covered set. This set pays for revenue the market believes recurs, so a commercial base under pressure is associated with the lowest pricing in the range even where margin holds up.

9. 09
   03 · VALUATION DRIVERS

   What the Premium End Has That the Discount End Does Not

   This page compares median EV/Revenue between faster- and slower-growing rated companies, split at 14% revenue growth.

   Splitting the rated names at 14% forward revenue growth, the faster growers trade at a median 7.4x EV/Revenue against 4.3x for the slower group. That gap is real but contained relative to the premium-to-discount spread shown earlier, which tells us growth alone doesn't explain most of the pricing difference. The larger driver appears to be confidence in the next readout — an association we draw from the data, not a proven cause. So what: growth is rewarded, but pipeline credibility still does most of the work.

   Everything on this page

   03 · VALUATION DRIVERS What the Premium End Has That the Discount End Does Not Median EV / Revenue (CY2027E) by revenue-growth cohort (split at the covered median, 14%) · rated names with growth estimates · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=5; slower n=4). Driver readings are NeuraCap views on the supplied data — association, not causation. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 9 EV/Revenue, median per cohort Growth Is Paid, at a Measured Premium Across the 9 names with CY2027E estimates, the 5 growing faster than the covered median price at 7.4x EV / Revenue against 4.3x for the 4 growing slower. Faster growth is associated with a higher multiple in this set, but the step is narrow enough that growth alone does not explain the top of the range. Runway to the Next Readout Is Inside the Multiple For a clinical-stage developer the balance sheet is part of the valuation, not a footnote. Names that can reach a value-inflecting readout without financing from a weak position carry a different risk profile from those that cannot, and the covered discount end is where that pressure tends to show. Exclusivity Runway Holds the Multiple Up Composition-of-matter protection, orphan and accelerated pathway designations and a clean safety characterisation are what make a forecast revenue tail believable. Where exclusivity is short or contested, the same forecast earns less credit on a forward revenue lens. Single-Asset Concentration Is the Discount You Can See A binary readout on one program, a crowded mechanism or an unagreed endpoint design are the detractors this market prices hardest. A reusable platform that has produced more than a lead asset is associated with the premium end of the covered set.

10. 10
    03 · SITUATION MAP

    Four Situations, Nine Covered Names: What the Market Is Paying for in Each

    This page maps the covered names into four situations by EV/Revenue and growth relative to the sector medians.

    We cut the covered set two ways — EV/Revenue against the sector median of 4.5x, and revenue growth against the covered median of 14% — to produce four situations. Each quadrant describes what the market is paying for in that combination, not a recommendation to buy or sell any name. Reading the tape this way surfaces which companies are priced for proof, which for growth, and which for neither. So what: this framework gives owners and buyers a shared vocabulary before any negotiation starts.

    Everything on this page

    03 · SITUATION MAP Four Situations, Nine Covered Names: What the Market Is Paying for in Each Cut on EV / Revenue vs the sector median (4.5x) (rows) and revenue growth vs the covered median (14%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 10 Paid up and Growing Fast Above-median multiple · above-median revenue growth 3 names Moderna, Inc. (MRNA) · Ascendis Pharma A/S (ASND) · MediciNova, Inc. (MNOV) Moderna, Inc. (MRNA), Ascendis Pharma A/S (ASND) and MediciNova, Inc. (MNOV) — 3 of the 9 names with estimates — price above the middle of the range and grow faster than 14%. MediciNova, Inc. (MNOV) carries the fastest covered growth at 94%, and a multiple that still looks full after a forward lens has credited that growth is the market paying for the pipeline behind the revenue line. Paid up on Established Revenue Above-median multiple · below-median revenue growth 2 names Amgen Inc. (AMGN) · Regeneron Pharmaceuticals, Inc. (REGN) Amgen Inc. (AMGN) at 3% growth and Regeneron Pharmaceuticals, Inc. (REGN) at 9% are the 2 names paid above the middle on slower top-line pace. Both hold strong margins — 44% and 36% respectively — so the pricing reads as payment for durability of marketed revenue rather than for speed. Fast Growth, Cautious Pricing Below-median multiple · above-median revenue growth 2 names Geron Corporation (GERN) · Alpha Cognition Inc. Common Stock (ACOG) Geron Corporation (GERN) at 45% growth and Alpha Cognition Inc. (ACOG) at 92% are the 2 names growing above the covered median while priced below the middle of the range. This is where the market is asking for evidence that a launch trajectory holds, and where a second program or a partner validation would change the read most. Discounted with Revenue Under Pressure Below-median multiple · below-median revenue growth 2 names AstraZeneca PLC (AZN) · Sarepta Therapeutics, Inc. (SRPT) AstraZeneca PLC (AZN) at 7% growth and Sarepta Therapeutics, Inc. (SRPT) at -24% are the 2 names below the middle on both measures. They are very different situations: AstraZeneca PLC (AZN) holds a 37% margin on a diversified marketed base, while Sarepta Therapeutics, Inc. (SRPT) is being priced on a commercial base the market has marked down.

11. 11
    03 · THE AGENDA

    Three Levers This Evidence Says the Market Pays For

    This page sets out three questions the pricing evidence says an owner or acquirer should resolve.

    The evidence points to three levers the market pays for: proving the platform beyond the lead asset, funding to the readout rather than to the calendar quarter, and deciding deliberately which economics to keep versus partner away. These are questions the cohort's own pricing puts on the table, not recommendations. Each has a concrete trigger: a second platform programme reaching human proof of concept, a financing completed ahead of the next readout, or a partner offer that prices territory rights above what retained economics can fund. So what: these are the operating decisions that can move a company from the discount end of this tape toward the premium end.

    Everything on this page

    03 · THE AGENDA Three Levers This Evidence Says the Market Pays For NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 11 Prove the Platform, Not Only the Lead Asset The premium end of the covered set is where more than one programme has come off the same modality. Directing spend so a second programme reaches human proof of concept shifts a company out of the single-asset frame the discount end shares. What changes the answer: A second programme from the same platform producing interpretable human data. Fund to the Readout, Not to the Quarter Cash runway measured against the catalyst calendar is part of how this set is valued, not a footnote to it. Sequencing spend so the next value-inflecting datapoint lands inside the runway changes the terms available on the capital that follows it. What changes the answer: A financing completed before, rather than after, the next readout. Decide Which Economics to Keep Partnering buys validation and capital, and it costs long-run ownership of the revenue tail. The recent tape shows regional and ex-US acquirers taking territory rights while majors take whole companies, so the choice of which rights to retain is a live commercial decision rather than a default. What changes the answer: A partner offer that prices territory rights above what retained economics can realistically fund.

12. 12
    SECTION 04

    04

    Section divider introducing the precedent transaction deal tape.

    We now move to the deal tape: what buyers actually paid to acquire biotechnology assets, from small bolt-ons to multi-billion-dollar purchases. Values are as recorded in the filings, and most records default to announced status.

    Everything on this page

    SECTION 04 04 THE DEAL TAPE Buyers Paid for Resolved Science, from Small Bolt-Ons to Multi-Billion Purchases Values are as recorded in the filings; several deal-value units are unresolved in the source and most records default to announced status. 04 of 06 Biotechnology Coverage | September 2026 | Confidential Sources & methodology 12

13. 13
    04 · DEAL CASE STUDIES

    Large-Cap Pharma Bought Resolved Assets; Specialist Capital Bought Portfolios

    This page profiles a small set of recorded transactions as case studies in buyer behaviour.

    We walk through a handful of the recorded transactions as case studies: large-cap pharma buying resolved assets outright, and specialist capital buying portfolios instead of single programmes. Where a revenue multiple is disclosed, the tape shows deals struck at 24.0x and 4.9x EV/Revenue — bracketing, but not directly comparable to, the public CY2027E basis shown earlier. The pattern across these cases is buyers engaging early and paying materially more once a clinical question has resolved. So what: the deal tape confirms the same probability-pricing logic we see in public markets, playing out in real transactions.

    Everything on this page

    04 · DEAL CASE STUDIES Large-Cap Pharma Bought Resolved Assets; Specialist Capital Bought Portfolios 3 of 27 recorded transactions, told as case studies · multiples on LTM financials at announcement where disclosed · the complete tape is in the appendix · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. 44 tape record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 41 recorded transactions with neither a disclosed value nor a multiple are omitted from the tape and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 13 Apr-2025 $115M Nordic Capital Epsilon SCA, SICAV-RAIF Nordic Capital Epsilon's $115M approach to PureTech Health plc puts specialist capital on the tape EV / LTM revenue 24.0x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The tape records an announced transaction with a specialist life-science capital provider on the buy side rather than a pharma acquirer. That structure suggests a buyer underwriting a spread of programmes and the capital behind them, not a single molecule awaiting one readout. HOW THE TARGET WAS VALUED The record shows $115M of value at 24.0x EV / Revenue, on the value as recorded in the filing. That sits well above the middle of the public set on a revenue lens, which is what gets paid when today's revenue line is early relative to the portfolio standing behind it. Mar-2023 $2.8B Sanofi Sanofi's $2.8B move for Provention Bio shows a major buying the asset once the science resolved EV / LTM revenue 4.9x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The tape carries only parties, value and announced status, so the logic has to be read from the shape of the deal. A large-cap acquirer taking a focused developer whole, rather than licensing territory rights, suggests the buyer wanted full ownership of the programme and its label economics. HOW THE TARGET WAS VALUED The record shows $2.8B at 4.9x EV / Revenue on the deal's own revenue basis. That benchmarks close to where the middle of this public set prices on forward revenue, a reminder that a majority purchase of a late-stage asset need not clear the public premium end. May-2022 $60M Vertex Pharmaceuticals Incorporated acquires Catalyst Biosciences, Inc. EV / LTM revenue 10.8x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced. HOW THE TARGET WAS VALUED The filing records $60M of enterprise value, struck at 10.8x LTM revenue.

14. 14
    SECTION 05

    05

    Section divider introducing strategic implications for owners, management teams and buyers.

    We close the analysis by turning pricing evidence into action: what this data changes for owners, management teams and buyers over the next twelve months. We also flag what evidence would change our read.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS What This Evidence Changes for Owners, Management Teams and Buyers Operating moves the set appears to reward, and the evidence that would change the read. 05 of 06 Biotechnology Coverage | September 2026 | Confidential Sources & methodology 14

15. 15
    05 · STRATEGIC IMPLICATIONS

    What the Pricing Evidence Means for Owners, Management Teams and Buyers

    This page sets out what the pricing evidence means for owners, management teams and acquirers.

    For owners, value steps at data rather than at quarters, which makes the useful question which part of the portfolio the market is paying for today. For management teams, concentration on a single asset, unsettled endpoints and sole-source supply are the detractors we associate with the discount end, and each is an operating fix rather than a messaging one. For acquirers and partners, the tape rewards patience through the readout and decisiveness once it resolves, so knowing which counterparties face a coming loss of exclusivity is practical intelligence. So what: each audience has a distinct, actionable lever inside the same evidence set.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS What the Pricing Evidence Means for Owners, Management Teams and Buyers NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 15 FOR OWNERS Value Steps at Data, Not at Quarters Because the lead lens is forward, today's price already credits the growth in the estimate. That makes the useful question which part of the portfolio the market is paying for and which part it is discounting, and where capital allocation can move a programme from the second category to the first. FOR MANAGEMENT TEAMS Concentration Is the Gap You Can Narrow Single-asset concentration, unsettled endpoint design and sole-source drug substance are the detractors associated with the discount end of this covered set. Securing supply, widening the programme base off one modality and tightening the target product profile against standard of care are operating moves, not messaging. FOR ACQUIRERS AND PARTNERS The Tape Rewards Patience, Then Decisiveness The recent records show buyers engaging at small values early and paying materially more once a clinical question has resolved. For a buyer, the practical work is holding a view on probability ahead of the readout; for a target, it is knowing which counterparties are structurally motivated by a coming loss of exclusivity.

16. 16
    SECTION 06

    06

    Section divider introducing the full comparables universe, methodology and sources.

    The final section carries the full universe, the valuation methodology, and the source for every disclosure behind the figures in this report. It's the reference section for anyone who wants to trace a number back to its filing.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Biotechnology Coverage | September 2026 | Confidential Sources & methodology 16

17. 17
    06 · PUBLIC COMPARABLES (1 OF 1)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This appendix lists all rated and unrated public comparables grouped by valuation tier.

    This table carries the rated companies plus the names without an eligible EV/Revenue multiple, grouped by valuation tier. Shading marks whether a name sits above or below the sector median, and tickers link back to the underlying source. This is the full comparables set behind every multiple quoted earlier in the report. So what: it lets a client verify our tiering against the underlying data directly.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 1) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (4.5x); amber marks below · 9 rated companies; 76 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. All 9 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 17 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥7.4x · median 23.3x · 3 companies MediciNova, Inc. MNOV Clinical-stage therapeutics developers $68M 68.5x 94% n/a n/a Moderna, Inc. MRNA Clinical-stage therapeutics developers $55.7B 23.3x 14% n/a n/a Ascendis Pharma A/S ASND Clinical-stage therapeutics developers $15.0B 7.4x 47% 42% 89 CORE — 3.1x–7.4x · median 4.5x · 3 companies Amgen Inc. AMGN Diversified commercial-stage biopharma $249B 6.2x 3% 44% 48 Regeneron Pharmaceuticals, Inc. REGN Clinical-stage therapeutics developers $82.8B 4.5x 9% 36% 45 AstraZeneca PLC AZN Diversified commercial-stage biopharma $277B 4.1x 7% 37% 44 DISCOUNT — <3.1x · median 2.6x · 3 companies Geron Corporation GERN Clinical-stage therapeutics developers $1.0B 3.1x 45% n/a n/a Alpha Cognition Inc. Common Stock ACOG Clinical-stage therapeutics developers $129M 2.6x 92% n/a n/a Sarepta Therapeutics, Inc. SRPT Clinical-stage therapeutics developers $2.4B 1.7x -24% 24% 0

18. 18
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    The Full Deal Tape, Newest First

    This appendix page lists the first half of the recorded precedent transactions, newest first.

    This page carries the first portion of the recorded transactions in this tier, newest first, with deal values linked to the underlying filing where disclosed. Several records carry data-quality flags — an unresolved deal-value unit, a reassigned divestiture role, or a collapsed duplicate filing — and are shown as recorded rather than adjusted. Deal multiples here are LTM at announcement, not directly comparable to the CY2027E public basis used elsewhere in this report. So what: this is the evidentiary record behind the deal-tape conclusions in the earlier sections.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) The Full Deal Tape, Newest First 27 recorded transactions in this tier · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. 44 tape record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 41 recorded transactions with neither a disclosed value nor a multiple are omitted from the tape and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 27 transactions shown; the rest are in the companion workbook. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 18 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2026 Gyro Therapeutics, Inc. → Cullgen Inc. $300M n/a n/a Gyro Therapeutics, Inc. acquired Cullgen Inc. in Mar-2026 at $300M enterprise value, recorded as closed. It is one of 2 records on this tape marked closed rather than announced, which makes it the more settled of the recent marks in the set. Jan-2026 Eli Lilly and Company → Ventyx Biosciences, Inc. $1.2B n/a n/a Eli Lilly and Company announced the purchase of Ventyx Biosciences, Inc. in Jan-2026 at $1.2B. A buyer of this scale taking a whole clinical-stage company, rather than a territory licence, suggests the clinical data package had moved far enough for the acquirer to want the asset outright. Dec-2025 Akebia Therapeutics, Inc. → Q32 Bio Inc. $595M n/a n/a Akebia Therapeutics, Inc. announced the acquisition of Q32 Bio Inc. in Dec-2025 at $595M. Mid-cap acquirers appear on this tape alongside the majors, which is consistent with a market where pipeline replenishment is not confined to the largest balance sheets. Aug-2025 Olaplex Holdings, Inc. → Purvala Bioscience, Inc. $10M n/a n/a Olaplex Holdings, Inc. announced the acquisition of Purvala Bioscience, Inc. in Aug-2025 at $10M, the smallest value recorded on this tape. Buyers from outside the therapeutics set do transact at the early science end, and at this size the purchase reads as capability rather than a revenue-bearing asset. Apr-2025 Nordic Capital Epsilon SCA, SICAV-RAIF → PureTech Health plc $115M 24.0x n/a Nordic Capital Epsilon SCA, SICAV-RAIF announced an approach to PureTech Health plc in Apr-2025 at $115M. Dedicated life-science and structured-capital providers are the marginal buyers of risk between readouts, and they price the same probability-weighted cash flows an acquirer does. Jun-2024 Bellevue Life Sciences Acquisition Corp. → OSR Holdings Co., Ltd. $245M n/a n/a Bellevue Life Sciences Acquisition Corp. announced a combination with OSR Holdings Co., Ltd. in Jun-2024 at $245M. Vehicle-led combinations are part of the same capital continuum as public financings, and they tend to appear where the public market has been hard to access. Jun-2023 Novartis AG → Chinook Therapeutics $3.5B n/a n/a Novartis AG announced the acquisition of Chinook Therapeutics in Jun-2023 at $3.5B, the highest recorded value among these 9 deals. It sits with the pattern of majors paying up once a programme has progressed toward a registrational package. Apr-2023 GENFIT → Versantis AG $46M n/a n/a GENFIT announced the acquisition of Versantis AG in Apr-2023 at $46M. Small, targeted purchases like this are how developers add an adjacent programme without taking on a second commercial infrastructure. Mar-2023 Sanofi → Provention Bio $2.8B 4.9x n/a Sanofi announced the acquisition of Provention Bio in Mar-2023 at $2.8B. A major paying this level for a single-focus developer is consistent with buying after the clinical question has largely resolved rather than before it.

19. 19
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    The Full Deal Tape, Newest First

    This appendix page continues the full deal tape, completing the list of recorded transactions.

    This page completes the deal tape, carrying the remainder of the recorded transactions with the same disclosure and data-quality conventions as the prior page. Records without a disclosed value or multiple are held in the companion workbook rather than shown here. Taken together, the two pages give a client the entire recorded transaction history behind our deal-tape commentary. So what: nothing in our case studies or commentary rests on a transaction a client can't independently trace.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) The Full Deal Tape, Newest First 27 recorded transactions in this tier · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-15 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-15; company disclosures via SEC EDGAR where linked. 44 tape record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 41 recorded transactions with neither a disclosed value nor a multiple are omitted from the tape and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 27 transactions shown; the rest are in the companion workbook. Biotechnology Coverage | September 2026 | Confidential Sources & methodology 19 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Oct-2022 YA II PN, Ltd. → Kiromic BioPharma, Inc. $50M n/a n/a Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced. Sep-2022 Ginkgo Bioworks Holdings, Inc. → Zymergen Inc. $5M n/a n/a Value shown as recorded in the filing; deal value unit unresolved, parent financials detached, status defaulted announced. May-2022 Vertex Pharmaceuticals Incorporated → Catalyst Biosciences, Inc. $60M 10.8x n/a Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced. Mar-2022 Comera Life Sciences Holdings, Inc. → OTR Acquisition Corp. $126M n/a n/a Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced. Oct-2021 Alexion Therapeutics, Inc. → Caelum Biosciences, Inc. $150M n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2021 Sanofi → Translate Bio $3.2B n/a n/a Value shown as recorded in the filing; deal value unit unresolved. Jul-2021 Capstar Special Purpose Acquisition Corp. → Gelesis, Inc. $900M n/a n/a Value shown as recorded in the filing; deal value unit unresolved, status defaulted announced. May-2021 Soaring Eagle Acquisition Corp. → Ginkgo Bioworks, Inc. $12.5B 125.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Apr-2021 Seneca Biopharma, Inc. → Palisade Bio, Inc. $1.6B 162469.0x n/a Value shown as recorded in the filing; status defaulted announced.

20. 20
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This page documents the report's sources, valuation assumptions and data-quality exclusions.

    This page sets out how the report was built: the valuation basis, what was excluded and why, and where each underlying disclosure lives. We treat this as the reference a client checks before relying on any figure in the deck. So what: transparency on method is what lets the earlier conclusions stand up to scrutiny.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-15 Typeface note: NeuraCap brand face is Kallisto Medium; this build renders in a standard sans (Arial) and should be reviewed in the brand face before external distribution. Biotechnology Coverage | September 2026 | Confidential 20 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (9 of 85 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Biotechnology and it clears the coverage gate with 65 of 85 companies (76%). EV / EBITDA, P / E are carried as a cross-check. DATA QUALITY & EXCLUSIONS 397 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 1991 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (1990) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

21. 21

    Forward Pricing Here Pays for Probability That Has Already Been Proven.

    Closing page restating the report's core conclusion that forward pricing rewards already-proven probability.

    Forward pricing here pays for probability that has already been proven, not for a promise still to be tested. The companion tables carry the full universe, the exclusion ledger and the complete source index for any figure a client wants to trace.

    Everything on this page

    Forward Pricing Here Pays for Probability That Has Already Been Proven. NeuraCap AI — Biotechnology Coverage September 2026 · Prepared by NeuraCap AI · Confidential Biotechnology Coverage | September 2026 | Confidential Sources & methodology 21

More coverage in Health Care

• Bi-Weekly Update · Sep 11, 2026Biotechnology Bi-Weekly Industry Events & M&A Update — August 28 – September 11, 2026